Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What is the rationale for using pembrolizumab in combination with chemotherapy in the first-line treatment of advanced urothelial cancer? (0:14)
- Could you give us an overview of the aims and design of the KEYNOTE-361 trial? (1:58)
- What were the efficacy and safety findings of this study? (3:40)
- Why do you think the primary endpoint was not met? (5:54)
- How will these findings impact on the role of pembrolizumab in the treatment of advanced urothelial cancer and what future studies involving pembrolizumab in urothelial cancer are planned or are in progress? (8:40)
Speaker Disclosure: Ajjai Alva has been an advisory board member/consultant for Merck Sharp & Dohme Corp, Bristol-Myers Squibb, AstraZeneca, Genentech, Roche, Pfizer, Progenics and Prometheus; has received travel/accommodations/expenses from Merck Sharp Dohmen Corp, Bristol-Myers Squibb and has received research funding through institution from Merck Sharp & Dohme, AstraZeneca, Bristol-Myers Squibb, Astellas, Seattle Genetics, Genentech, Pfizer, Progenics, Prometheus, Eli Lilly, ASCO, Celgene and Harpoon Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. The KEYNOTE-361 trial was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Filmed in coverage of the Virtual 2020 ESMO Congress.
PFS = progression-free survival.
Share this Video
Related Videos In Genitourinary Cancers
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Ajjai Alva, ESMO 2020 – Pembrolizumab plus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma: the KEYNOTE-361 trial
Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!